IP Library › Granted Patent US 10,377,830
Granted Patent B2
US 10,377,830 · App. 15/978,699 · Granted Aug 13, 2019

Method of treating IgA nephropathy by administering humanized APRIL-binding antibodies

Inventors: Hans van Eenennaam (Nijmegen, NL); Andrea van Elsas (Oss, NL); David Lutje Hulsik (Nijmegen, NL); Jan Paul Medema (Nieuw Vennep, NL)
Assignee: ADURO BIOTECH HOLDINGS, EUROPE B.V.
C07K16/2875A61K39/3955A61K45/06G01N33/564G01N33/57488A61K2039/505C07K2317/24C07K2317/30C07K2317/33C07K2317/56C07K2317/565C07K2317/567C07K2317/76C07K2317/92C07K2317/94G01N2800/24
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,377,830
App. No.
15/978,699
Granted
Aug 13, 2019
Kind
B2
Abstract

The invention relates to APRIL-binding antibodies, which bind the same epitope of human APRIL as an antibody having an antigen binding site of hAPRIL.01A. The antibodies of the present invention comprise specific selections of framework sequences of the V H and V L domains and have unexpected features in comparison to hAPRIL.01A. The invention further relates to compositions comprising an antibody of the invention and to the medical and diagnostic uses of the antibodies and compositions.

Claims (6)

1. A method of treating IgA nephropathy in an individual in need thereof, comprising:

administering to the individual an effective amount of a humanized antibody having (i) light chain complementary determining regions of SEQ ID NO: 8, SEQ ID NO: 9, and SEQ ID NO: 10, (ii), heavy chain complementary determining regions of SEQ ID NO: 5, SEQ ID NO: 6, and SEQ ID NO: 7, and framework regions having at least 90% sequence similarity to the framework regions of SEQ ID NO: 50 and SEQ ID NO: 52, wherein the antibody binds to human “A proliferation-inducing ligand” (“APRIL”) protein.

2. A method according to claim 1 , wherein at least 90% sequence similarity is at least 90% sequence identity.

3. A method according to claim 1 , wherein at least 90% sequence similarity is at least 95% sequence similarity.

4. A method according to claim 3 , wherein at least 95% sequence similarity is at least 95% sequence identity.

5. A method according to claim 1 , wherein the antibody is a humanized antibody having a light chain of SEQ ID NO: 50 and a heavy chain of SEQ ID NO: 52.

Assignments (5)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: MEDEMA, JAN PAUL
To: ACADEMISCH MEDISCH CENTRUM
Reel/Frame 045820/0141 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: ACADEMISCH MEDISCH CENTRUM
To: ADURO BIOTECH HOLDINGS, EUROPE B.V.
Reel/Frame 045820/0184 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: HULSIK, DAVID LUTJE
To: ADURO BIOTECH EUROPE B.V.
Reel/Frame 045820/0289 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: ADURO BIOTECH EUROPE B.V.
To: ADURO BIOTECH HOLDINGS, EUROPE B.V.
Reel/Frame 045820/0376 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 16, 2018
From: #EEN B.V.; VAN EENENNAAM, HANS; VAN ELSAS, ANDREA; IREYA B.V.
To: ADURO BIOTECH HOLDINGS, EUROPE B.V.
Reel/Frame 045820/0439 →
Priority Claims (1)
NL 2014108 · Jan 9, 2015 · national
Continuity (2)
Division 14991708 · Jan 8, 2016
Related Publication 20180258176A1 · Sep 13, 2018
Cited By (5)
US 12,202,882 US 12,304,943 US 12,612,446 US 12,612,447 US 12,715,934